Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
RheumaGen logo — RheumaGen is developing an HLA gene editing platform to cure...

RheumaGen

RheumaGen is developing an HLA gene editing platform to cure Rheumatoid Arthritis and other autoimmune diseases.

Founded 2019 United States Denver, United States 7 employees Venture round Biotechnology, Life Sciences

General Information

Company Name RheumaGen
Founded Year 2019
Location United States Denver, United States
Employees 7
Industries Biotechnology, Life Sciences
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with RheumaGen. To contact RheumaGen, visit rheumagen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does RheumaGen compare?

A PDF of RheumaGen and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting RheumaGen soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About RheumaGen

RheumaGen is a biotechnology startup based in the United States that is focused on developing a cutting-edge HLA gene editing platform to address Rheumatoid Arthritis and other autoimmune diseases. The company, established in 2019, is driven by the mission of creating a groundbreaking gene editing treatment with the potential to cure Rheumatoid Arthritis, offering hope to millions of individuals suffering from this debilitating condition. With its innovative approach, RheumaGen aims to revolutionize the treatment landscape for autoimmune diseases, positioning itself at the forefront of the biotechnology and life sciences industries. As the startup continues to progress, it presents an intriguing opportunity for venture capital firms seeking to invest in pioneering solutions for significant unmet medical needs.

No funding data available for RheumaGen yet.

RheumaGen Alternatives & Competitors

View All Alternatives
RheumaGen vs
NewBiologix
NewBiologix Switzerland

Developing technologies for the biopharma industry to allow them to treat the root causes of diseas...

Series A
25 employees
Biotechnology, Health Care
RheumaGen vs
Tessera Therapeutics
Tessera Therapeutics

Pioneering the future of genetic medicine with the power to rewrite the genome and cure diseases at...

21 employees
Biopharma, Biotechnology
RheumaGen vs
Affinia Therapeutics
Affinia Therapeutics United States

Building the next generation of gene therapies

Series C
30 employees
Biotechnology, Health Care
View all alternatives

FAQ About RheumaGen

RheumaGen is developing an HLA gene editing platform to cure Rheumatoid Arthritis and other autoimmune diseases.
RheumaGen was founded in 2019.
RheumaGen is headquartered in Denver, United States.
RheumaGen operates in Biotechnology and Life Sciences.
RheumaGen has approximately 7 employees.
Top alternatives and competitors to RheumaGen include NewBiologix, Tessera Therapeutics, Affinia Therapeutics, Taysha Gene Therapies, Apic Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
RheumaGen and NewBiologix are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for RheumaGen, https://bouncewatch.com/company/rheumagen, updated 23 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout